Hesperadin: ATP-Competitive Aurora B Kinase Inhibitor for Mitotic Control

Executive Summary: Hesperadin is an ATP-competitive small molecule that selectively inhibits Aurora B kinase at nanomolar concentrations, disrupting mitotic progression and chromosome segregation (ApexBio). Its sulphonamide moiety inserts into the ATP-binding pocket of Aurora B, extending inhibition to an adjacent hydrophobic region. Hesperadin’s cellular effects include loss of Ser-10 histone H3 phosphorylation and induction of polyploidization in HeLa cells. The compound is widely used to interrogate spindle assembly checkpoint (SAC) function and cell cycle regulation in cancer research (PNAS 2019). Hesperadin is minimally active against Cdk1/cyclin B and Cdk2/cyclin E at higher concentrations, providing pathway specificity.

Biological Rationale

Aurora B kinase is a serine/threonine kinase that regulates chromosome condensation, alignment, and segregation during mitosis (Kaisaria et al., 2019). It is a core component of the chromosomal passenger complex (CPC), which monitors mitotic progression and ensures correct kinetochore-microtubule attachments. Dysregulation of Aurora B activity leads to aneuploidy, failed cytokinesis, and tumorigenesis. The spindle assembly checkpoint (SAC) prevents premature anaphase onset until all chromosomes achieve bi-orientation. Small molecule inhibitors like Hesperadin allow precise dissection of these mitotic processes and are essential for dissecting the molecular basis of chromosome missegregation in disease models.

Mechanism of Action of Hesperadin

Hesperadin is an ATP-competitive inhibitor. It binds the ATP-binding pocket of Aurora B kinase, with its sulphonamide group extending into an adjacent hydrophobic pocket, thereby occluding ATP access (ApexBio). This prevents Aurora B autophosphorylation and substrate phosphorylation. Hesperadin’s IC₅₀ for Aurora B is 250 nM in purified enzyme assays. In cellular systems, Hesperadin inhibits histone H3 Ser-10 phosphorylation—a canonical biomarker of Aurora B activity—with an IC₅₀ of 40 nM. The compound also inhibits Aurora A kinase, but with significantly reduced potency, and shows minimal inhibition of Cdk1/cyclin B and Cdk2/cyclin E even at micromolar concentrations. This selectivity profile ensures that effects on mitosis can be attributed primarily to Aurora B inhibition. Cellular phenotypes following Hesperadin treatment include disrupted chromosome alignment, polyploidization up to 32C DNA content, and formation of enlarged, lobed nuclei in HeLa cells.

Evidence & Benchmarks

• Hesperadin inhibits purified Aurora B kinase with an IC₅₀ of 250 nM, measured in in vitro kinase assays (ApexBio).
• Hesperadin blocks Ser-10 histone H3 phosphorylation in HeLa cells with an IC₅₀ of 40 nM, as quantified by immunoblotting (ApexBio).
• Cellular treatment with Hesperadin leads to failure of chromosome alignment and segregation, as visualized by DAPI staining and live-cell imaging (PNAS 2019).
• HeLa cells exposed to Hesperadin do not arrest growth, but become polyploid (up to 32C), indicating cytokinesis failure (Malotilate.com).
• Minimal off-target inhibition is observed for Cdk1/cyclin B and Cdk2/cyclin E, with significant effects only at concentrations >10 μM (5-hme-ctp.com).

Applications, Limits & Misconceptions

Hesperadin is a benchmark tool in studies of mitotic regulation, SAC disruption, and Aurora kinase signaling in cancer and cell cycle research. Its rapid and reversible action enables precise temporal control in cell-based assays. The compound supports interrogation of chromosome missegregation and polyploidization mechanisms.

Compared to other resources, this article further details Hesperadin’s cellular phenotypes and selectivity, extending prior summaries by providing explicit benchmarks for IC₅₀ and off-target profiles.

Cross-referencing other site articles that cover Hesperadin’s workflow integration, this review updates practical handling tips and clarifies key cellular endpoints for translational research.

Common Pitfalls or Misconceptions

• Hesperadin is not a pan-kinase inhibitor: Its selectivity for Aurora B over Cdk1 and Cdk2 is confirmed up to 10 μM, minimizing confounding off-target effects.
• Not suitable for long-term storage in solution: Hesperadin solutions are unstable and should be freshly prepared; prolonged storage reduces potency (ApexBio).
• Not water-soluble: Hesperadin is insoluble in water; dissolve in DMSO (≥25.85 mg/mL) or, with warming/sonication, in ethanol.
• Does not arrest cell growth: Hesperadin halts proliferation (division), but cells continue to grow and become polyploid.
• Cannot distinguish Aurora A from B inhibition at high doses: At high concentrations, partial Aurora A inhibition may confound results.

Workflow Integration & Parameters

For experimental use, dissolve Hesperadin in DMSO at ≥25.85 mg/mL. Store aliquots at -20°C as a solid. Solutions should not be stored long-term; use within hours of preparation. For cell-based assays, treat cultures with Hesperadin at 20–100 nM for 1–24 hours, monitoring mitotic markers (e.g., phospho-H3 Ser-10) and nuclear morphology.

Compared to the workflow guides, this article provides updated solubility data and clarifies optimal dosing for cellular phenotypes.

Key endpoints include loss of chromosome alignment, increased DNA content (flow cytometry), and reductions in SAC function (Mad2/BubR1 localization). For pathway dissection, co-treatments with other kinase inhibitors or RNAi can isolate Aurora B-specific effects.

Conclusion & Outlook

Hesperadin is a gold-standard ATP-competitive Aurora B kinase inhibitor for dissecting mitotic control and spindle assembly checkpoint regulation. Its well-characterized selectivity and robust cellular phenotypes make it a primary tool for cancer research and pathway mapping. As new studies further refine the mechanisms of SAC disassembly and Aurora kinase signaling (Kaisaria et al., 2019), Hesperadin will remain central to experimental design and translational research in cell cycle regulation.

For detailed protocols and ordering information, visit the Hesperadin product page (A4118 kit).